Genenta Science S.p.A., a clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. The company's lead product candidate is Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated MGMT gene promoter. It is also developing Temferon for use in the treatment of other solid tumor indications, locally advanced hepatocellular carcinoma, and intra-hepatic cholangiocarcinoma. The company was incorporated in 2014 and is headquartered in Milan, Italy.
IPO Year: 2021
Exchange: NASDAQ
Website: https://www.genenta.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 6/29/2023 | $15.00 | Buy | ROTH MKM |
| 7/25/2022 | $25.00 | Buy | H.C. Wainwright |
ROTH MKM resumed coverage of Genenta S.p.A. with a rating of Buy and set a new price target of $15.00
H.C. Wainwright initiated coverage of Genenta S.p.A. with a rating of Buy and set a new price target of $25.00
6-K - Genenta Science S.p.A. (0001838716) (Filer)
6-K - Genenta Science S.p.A. (0001838716) (Filer)
6-K - Genenta Science S.p.A. (0001838716) (Filer)
6-K - Genenta Science S.p.A. (0001838716) (Filer)
424B5 - Genenta Science S.p.A. (0001838716) (Filer)
6-K - Genenta Science S.p.A. (0001838716) (Filer)
6-K - Genenta Science S.p.A. (0001838716) (Filer)
20-F/A - Genenta Science S.p.A. (0001838716) (Filer)
S-8 - Genenta Science S.p.A. (0001838716) (Filer)
20-F - Genenta Science S.p.A. (0001838716) (Filer)
MILAN and NEW YORK, Oct. 23, 2024 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ:GNTA), a pioneer in immuno-oncology and in cell-based therapeutics, is pleased to announce that Pierluigi Paracchi, CEO, will attend as a speaker to the Italy-U.S. meeting "Cross-Border Investments and Strategies in the Biotechnology Sector: A Transatlantic Perspective" scheduled at 2.00 PM on October 25th, 2024 at the U.S. Senate - Washington, D.C. The event is organized by the U.S. National Security Commission on Emerging Biotechnology (NSCEB) and the Italian Embassy in the U.S. The upcoming mission to Washington, D.C. is part of the strategic plan of the Italian Working Group on the Internationalizati
MILAN and NEW YORK, Oct. 02, 2024 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ:GNTA), a pioneer in immuno-oncology and a leader in cell-based therapeutics, is pleased to announce that the Agenzia Italiana del Farmaco (AIFA) has approved a new Phase 1 clinical trial for metastatic Renal Cell Cancer (mRCC), marking a significant expansion of the potential applications for Genenta's flagship product, Temferon™. This approval by AIFA is in line with the standards that are harmonized across European regulatory frameworks established by the European Medicines Agency (EMA). From the CEO's Desk: Pierluigi Paracchi, CEO and Co-founder of Genenta, stated: "This approval to initiate a Phase 1 trial i
MILAN, Italy and NEW YORK, May 06, 2024 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ:GNTA), a clinical-stage immuno-oncology company developing a cell-based platform harnessing the power of hematopoietic stem cells to provide durable and safe treatments for solid tumors, announces that it held its Ordinary and Extraordinary Shareholders' Meeting on May 2, 2024. At the Ordinary and Extraordinary Shareholders' Meeting, the Company's shareholders approved the appointment of five directors to the Company's Board of Directors, effective as of May 2, 2024, including four new members. The new members of the Board include: John L. Cantello, Ph.D., Lauren H. Chung, Ph.D., Armon R. Sharei, Ph.D. and
MILAN, Italy and NEW YORK, Feb. 08, 2024 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ:GNTA), a clinical-stage immuno-oncology (I/O) company developing a cell-based platform harnessing the power of hematopoietic stem cells to provide durable and safe treatments for solid tumors, today announced that: We have successfully dosed the first of three patients in Cohort 8 (Temferon™ at 4x10^6/kg), the last cohort of the Phase 1 dose-ranging part of the Phase 1/2 clinical trial in newly diagnosed uMGMT Glioblastoma Multiforme (TEM-GBM) patients. The second patient has been enrolled and the treatment is planned. Thus far, the preliminary data indicate no dose-limiting toxicities related to Temfero
MILAN, Italy and NEW YORK, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Genenta Science S.p.A. (NASDAQ:GNTA) a clinical-stage immuno-oncology company developing a cell-based platform harnessing the power of hematopoietic stem cells towards a permanent self-vaccination against cancer, will present at several upcoming scientific and investor conferences. H.C. Wainwright 25th Annual Global Investment Conference, September 11-13 2023, NYC-USPresenters: Pierluigi Paracchi, CEO and Co-founder, Carlo Russo, CMO and Head of Development 2023 Cantor Global Healthcare Conference, September 26-28 2023, NYC-USPresenters: Pierluigi Paracchi, CEO and Co-founder, Richard Slansky, CFO Chardan's 7th Annual Genetic
Company Selects Refractory Advanced Genitourinary Malignancies including Renal Cell Cancer as Second Indication MILAN, Italy and NEW YORK, July 28, 2023 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ:GNTA), a clinical-stage immuno-oncology (I/O) company developing a cell-based platform harnessing the power of hematopoietic stem cells to provide durable and safe treatments for solid tumors, today announced that: the Phase 1 dose-ranging clinical trial in Glioblastoma Multiforme (TEM1-GBM) is progressing in line with the development program. All the patients assigned to Cohort 7 (3x10E/kg Temferon™) are dosed.Enrollment of the patients in Cohort 8 (4x10E/kg) is completed.No dose-lim
MILAN, Italy and NEW YORK, June 29, 2023 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ:GNTA), a clinical-stage immuno-oncology company developing a cell-based platform harnessing the power of hematopoietic stem cells to provide durable and safe treatments for solid tumors, today announced that the European Commission has granted Orphan Drug Designation (ODD) to Temferon™ for the treatment of glioma. Glioblastoma Multiforme (GBM) is the first clinical indication of Temferon. ODD is granted by the European Commission for medicines in development to treat rare conditions affecting no more than five in 10,000 people in the European Union (EU), provided there is no other satisfactory treatme
MILAN, Italy and NEW YORK, May 16, 2023 (GLOBE NEWSWIRE) -- Luigi Naldini, Ph.D., M.D., co-founder and Executive Scientific Board Chairman of Genenta Science S.p.A. (NASDAQ:GNTA), a clinical-stage immuno-oncology company, will be presenting the company cell-based platform harnessing the power of hematopoietic stem cells to provide durable, safe, and well tolerated treatment for solid tumors at several upcoming scientific congresses. Prof. Luigi Naldini will provide updates on the efficacy of Genenta's lead product candidate, Temferon, in pre-clinical solid tumor models and preliminary clinical biological data confirming in patients at these congresses. Genenta has a deep pipeline of p
Funds available expected to be sufficient for Genenta to continue to operate into the first quarter of 2025Net exchange rate gain of €2.3 millionTax credit of €6.4 million MILAN, Italy and NEW YORK, April 26, 2023 (GLOBE NEWSWIRE) -- Genenta Science S.p.A. (NASDAQ:GNTA) a clinical-stage immuno-oncology company developing a cell-based platform harnessing the power of hematopoietic stem cells to provide durable and safe treatments for solid tumors, today announced its fiscal year 2022 financial results and that it has filed its annual report on Form 20-F for the fiscal year ended December 31, 2022 (the "Annual Report") with the Securities and Exchange Commission ("SEC"). The Annual Report c
MILAN, Italy and NEW YORK, April 03, 2023 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ:GNTA), a clinical-stage immuno-oncology company developing a cell-based platform harnessing the power of hematopoietic stem cells to provide durable and safe treatments for solid tumors, today announced that the license agreement with Ospedale San Raffaele (OSR) has been amended and restated to provide access to all solid tumor indications, subject to governmental consent as described below. "We are pleased to reaffirm Genenta's collaboration with OSR by expanding our license agreement and providing our platform access to all solid tumor indications," said Pierluigi Paracchi, Chief Executive Officer of G
MILAN, Italy and NEW YORK, May 06, 2024 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ:GNTA), a clinical-stage immuno-oncology company developing a cell-based platform harnessing the power of hematopoietic stem cells to provide durable and safe treatments for solid tumors, announces that it held its Ordinary and Extraordinary Shareholders' Meeting on May 2, 2024. At the Ordinary and Extraordinary Shareholders' Meeting, the Company's shareholders approved the appointment of five directors to the Company's Board of Directors, effective as of May 2, 2024, including four new members. The new members of the Board include: John L. Cantello, Ph.D., Lauren H. Chung, Ph.D., Armon R. Sharei, Ph.D. and
Corium Pharma Solutions, Inc. ("Corium Pharma Solutions" or "CPSI"), a leading, full-service contract development and manufacturing organization specializing in novel drug delivery technologies, including transdermal modalities, today announced the appointment of Dr. Mark Sirgo as Chief Executive Officer and member of the Board of Directors. Dr. Sirgo is a pharmaceutical executive with over 35 years' experience in the industry, including founding and serving as the President, Chief Executive Officer, and Vice Chairman of BioDelivery Sciences International, Inc. ("BDSI"), a commercial-stage specialty pharmaceutical company focused on pain and addiction management. During his tenure at BDSI,
MILAN, Italy and NEW YORK, May 09, 2022 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ:GNTA), a clinical-stage biotechnology company pioneering the development of hematopoietic stem progenitor cell immuno-gene therapy for cancer, announces the appointment of Tim Obara, a highly experienced commercial healthcare executive, as Vice President Business Development. Tim has significant experience across a broad range of therapeutic areas and with global responsibility. He joins Genenta from the University of Pennsylvania Gene Therapy Program, where he was Executive Director of Research Operations. He has previously worked in senior business development roles at Amicus Therapeutics, AstraZeneca, G
SC 13G/A - Genenta Science S.p.A. (0001838716) (Subject)
SC 13G/A - Genenta Science S.p.A. (0001838716) (Subject)
SC 13G - Genenta Science S.p.A. (0001838716) (Subject)
SC 13G - Genenta Science S.p.A. (0001838716) (Subject)
SC 13G - Genenta Science S.p.A. (0001838716) (Subject)
HC Wainwright & Co. analyst Joseph Pantginis reiterates Genenta Science (NASDAQ:GNTA) with a Buy and maintains $25 price target.
Gainers Renalytix (NASDAQ:RNLX) stock rose 490.4% to $2.25 during Monday's regular session. The market value of their outstanding shares is at $112.4 million. Regencell Bioscience (NASDAQ:RGC) stock rose 39.91% to $10.39. The market value of their outstanding shares is at $135.2 million. Genenta Science (NASDAQ:GNTA) shares increased by 31.84% to $4.14. The market value of their outstanding shares is at $75.4 million. T2 Biosystems (NASDAQ:TTOO) stock rose 29.94% to $6.35. The company's market cap stands at $25.7 million. Sangamo Therapeutics (NASDAQ:SGMO) stock moved upwards by 26.04% to $0.72. The company's market cap stands at $128.3 million. Organovo Holdings (NASDAQ:ONVO) shares m
Shares of Urban Outfitters, Inc. (NASDAQ:URBN) dipped during Wednesday’s session after the company reported third-quarter financial results. Urban Outfitters reported quarterly earnings of 88 cents per share, topping the analyst consensus estimate of 82 cents per share. The company reported record quarterly sales of $1.28 billion which exceeded analyst expectations of $1.26 billion, according to data from Benzinga Pro. Urban Outfitters shares fell 9.9% to $32.73 on Wednesday. Here are some other stocks moving in today's mid-day session. Gainers AgileThought, Inc. (NASDAQ:AGIL) shares jumped 206.4% to $0.2514 after gaining 5% on Tuesday. PaxMedica, Inc. (NASDAQ:PXMD) rose 33% to $1.08
Roth MKM analyst Kumaraguru Raja assumes Genenta Science (NASDAQ:GNTA) with a Buy rating and announces Price Target of $15.
Genenta had a tax credit with a carrying value of €6.4 million and cash and cash equivalents of €29.8 million sufficient to allow it to continue to operate its business into the first quarter of 2025.
Temferon is a proprietary cell therapy designed to reprogram the tumor microenvironment by delivering immunomodulatory molecules directly to tumors. Genenta is testing Temferon in an ongoing Phase 1/2a clinical trial in newly diagnosed patients with GBM who have an unmethylated MGMT gene promoter (uMGMT-GBM).